856 related articles for article (PubMed ID: 19228622)
1. Gene-expression signatures in breast cancer.
Sotiriou C; Pusztai L
N Engl J Med; 2009 Feb; 360(8):790-800. PubMed ID: 19228622
[No Abstract] [Full Text] [Related]
2. [Molecular phenotypes of breast cancer and their clinical application].
Tang P; Wei B; Hicks DG; Skinner K; Bu H
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):13-7. PubMed ID: 19489219
[No Abstract] [Full Text] [Related]
3. Prediction of cancer outcome with microarrays.
Goldhirsch A; Gelber RD; Viale G; Colleoni M; Coates AS
Lancet; 2005 May 14-20; 365(9472):1685-6; author reply 1686. PubMed ID: 15894095
[No Abstract] [Full Text] [Related]
4. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
Correa Geyer F; Reis-Filho JS
Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611
[TBL] [Abstract][Full Text] [Related]
5. High genomic grade index associated with poor prognosis for lymph node-negative and estrogen receptor-positive breast cancers and with good response to chemotherapy.
Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
Cancer; 2011 Feb; 117(3):472-9. PubMed ID: 20878674
[TBL] [Abstract][Full Text] [Related]
6. Patient profiling in breast cancer--is knowledge power?
Kirk R; Villanueva MT; Hutchinson L
Nat Rev Clin Oncol; 2011 Dec; 9(1):1. PubMed ID: 22186933
[No Abstract] [Full Text] [Related]
7. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.
Cosler LE; Lyman GH
Cancer Invest; 2009 Dec; 27(10):953-9. PubMed ID: 19909009
[No Abstract] [Full Text] [Related]
10. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.
Huber KE; Carey LA; Wazer DE
Semin Radiat Oncol; 2009 Oct; 19(4):204-10. PubMed ID: 19732684
[TBL] [Abstract][Full Text] [Related]
11. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.
Abd El-Rehim DM; Ball G; Pinder SE; Rakha E; Paish C; Robertson JF; Macmillan D; Blamey RW; Ellis IO
Int J Cancer; 2005 Sep; 116(3):340-50. PubMed ID: 15818618
[TBL] [Abstract][Full Text] [Related]
12. The use of microarray technology in the management of breast cancer.
Pusztai L
Clin Adv Hematol Oncol; 2007 Mar; 5(3):193-4, 197. PubMed ID: 17519880
[No Abstract] [Full Text] [Related]
13. Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy.
Duffy MJ; McDermott EW; Crown J
Clin Chem; 2017 Apr; 63(4):804-806. PubMed ID: 28188230
[No Abstract] [Full Text] [Related]
14. [Molecular classification of breast cancer].
Zepeda-Castilla EJ; Recinos-Money E; Cuéllar-Hubbe M; Robles-Vidal CD; Maafs-Molina E
Cir Cir; 2008; 76(1):87-93. PubMed ID: 18492427
[TBL] [Abstract][Full Text] [Related]
15. Genetic profiling can predict chemotherapy side effects and treatment response.
Expert Rev Mol Diagn; 2003 Jul; 3(4):406-7. PubMed ID: 12877380
[No Abstract] [Full Text] [Related]
16. Breast cancer gene microarrays pass muster.
Twombly R
J Natl Cancer Inst; 2006 Oct; 98(20):1438-40. PubMed ID: 17047189
[No Abstract] [Full Text] [Related]
17. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling.
Zembutsu H; Suzuki Y; Sasaki A; Tsunoda T; Okazaki M; Yoshimoto M; Hasegawa T; Hirata K; Nakamura Y
Int J Oncol; 2009 Feb; 34(2):361-70. PubMed ID: 19148470
[TBL] [Abstract][Full Text] [Related]
18. The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
Cockburn JG; Hallett RM; Gillgrass AE; Dias KN; Whelan T; Levine MN; Hassell JA; Bane A
BMC Cancer; 2016 Jul; 16():555. PubMed ID: 27469239
[TBL] [Abstract][Full Text] [Related]
19. Profiling familial breast cancer.
Lakhani SR; O'Hare MJ; Ashworth A
Nat Med; 2001 Apr; 7(4):408-10. PubMed ID: 11283660
[No Abstract] [Full Text] [Related]
20. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
Sabine VS; Sims AH; Macaskill EJ; Renshaw L; Thomas JS; Dixon JM; Bartlett JM
Breast Cancer Res Treat; 2010 Jul; 122(2):419-28. PubMed ID: 20480226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
